Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.90 +0.12 (+0.42%)
Official Closing Price Updated: 7:00 PM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,885,364
Open 28.82
Bid (Size) 28.90 (81)
Ask (Size) 28.93 (7)
Prev. Close 28.78
Today's Range 28.64 - 28.94
52wk Range 25.20 - 36.94
Shares Outstanding 5,606,688,356
Dividend Yield 5.67%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 High-Yielding Stocks
Before interest rates come down, you may want to consider loading up on these terrific income stocks. 
Via The Motley Fool
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,... 
Via Benzinga

Performance

YTD
-2.79%
-2.79%
1 Month
-4.24%
-4.24%
3 Month
+2.12%
+2.12%
6 Month
+6.33%
+6.33%
1 Year
-20.56%
-20.56%

More News

Read More
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
Via Benzinga
Exposures COVID-19 Product Safety
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Pfizer's Options Frenzy: What You Need to Know
Via Benzinga
Is Pfizer Stock Ready to Bounce Back?
Via The Motley Fool
These 3 Stocks Pay You More Than 5% to Own Them
Via MarketBeat
Mr. Darren Walker, Dr. Albert Bourla, and Secretary General Jens Stoltenberg to be awarded Concordia Leadership Award at the 2024 Annual Summit this September
Via Send2Press
Value Investing: Unearthing 3 Hidden Gems in Today's Market
Via MarketBeat
Pfizer, Conagra Brands And 2 Other Stocks Insiders Are Selling
Via Benzinga
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
2 Cheap Passive Income Stocks to Buy Now
Via The Motley Fool
3 Top Value Stocks to Buy Right Now
Via The Motley Fool
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
Via Investor's Business Daily
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
Via Benzinga
Topics ETFs
Exposures COVID-19 Product Safety
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Via MarketBeat
Exposures COVID-19 Product Safety
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
Via The Motley Fool
3 Dividend Stocks to Double Up On Right Now
Via The Motley Fool
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
Via The Motley Fool
Why Pfizer Stock Slumped on Friday
Via The Motley Fool
Pfizer Slides Toward Sell Zone After BioNTech-Tied Covid/Flu Shot Misses Its Mark
Via Investor's Business Daily
Pfizer, BioNTech's COVID-19/Flu Combo Vaccine Fails To Meet Key Goal In Late-Stage Study
Via Benzinga
Exposures COVID-19
Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
Via Benzinga
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
From Pfizer Inc.
Via Business Wire
Eli Lilly Smashed Estimates Thanks To Unbelievable Demand For Its Diabetes And Weight Loss Blockbusters
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.